Key result
Elevated NT-proBNP in normoweight patients links to ~128% higher MACCE risk versus overweight patients without it.
Why the study?
Little was known about how body mass index modifies the prognostic value of NT-proBNP for clinical outcomes in patients with acute coronary syndrome.
Does body mass index modify the prognostic value of NT-proBNP for major adverse cardiovascular and cerebral events in patients with acute coronary syndrome?
Cohort (n=11,757)
No
Does body mass index modify the prognostic value of NT-proBNP for major adverse cardiovascular and cerebral events in patients with acute coronary syndrome?
The prognostic value of NT-proBNP in patients with acute coronary syndrome is significantly modified by body mass index, indicating that BMI should be factored into NT-proBNP-based risk stratification.
May refine risk stratification by NT-proBNP beyond BMI; hypothesis-generating interaction leaves causal and therapeutic implications open.
Little is known about the relationship between body mass index (BMI) and the prognostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with acute coronary syndrome (ACS). This study aimed to investigate how BMI modifies the association between NT-proBNP levels and clinical outcomes in ACS patients. A total of 11,757 ACS patients from the Cardiovascular Centre Beijing Friendship Hospital were recruited. The association between NT-proBNP and major adverse cardiovascular and cerebral events (MACCEs) was assessed using multivariate Cox proportional hazards models. The multiplicative interaction between NT-proBNP and BMI was evaluated using the Wald χ2 test. During the median follow-up time of 3.04 (IQR: 1.07‒5.02) years (33,232 person-years), 1996 MACCEs were documented. A significant multiplicative interaction was observed between natural logarithm (Ln)-NT-proBNP and BMI (p for multiplicative interaction = 0.013). The categorical thresholds of NT-porBNP for the risk of MACCEs were 1559, 155, and 419 pg/ml for normoweight, overweight, and obese patients, respectively. When NT-proBNP levels were near-normal or mildly elevated (≤ 300 pg/ml), overweight and obese patients exhibited a higher event probability than normoweight patients at a given NT-proBNP level. However, an opposite trend was observed at significantly elevated NT-proBNP levels (> 300 pg/ml), with normoweight patients showing a higher event probability. When BMI and NT-proBNP were considered jointly, normoweight patients with elevated NT-proBNP had a significantly higher risk of MACCEs than overweight patients without elevated NT-proBNP (hazard ratio: 2.28; 95% confidence interval: 1.83‒2.84; p < 0.001). The prognostic value of NT-proBNP in ACS patients varies with BMI, with the extent of NT-proBNP elevation playing a role in this relationship.
No takes yet. Share an insight, caveat, or question.
He et al. (2025) conducted a cohort in Acute coronary syndrome (n=11,757). Elevated NT-proBNP and normoweight BMI vs. Normal NT-proBNP and overweight BMI was evaluated on Major adverse cardiovascular and cerebral events (MACCEs) (HR 2.28, 95% CI 1.83-2.84, p=<0.001). Normoweight patients with elevated NT-proBNP had a significantly higher risk of major adverse cardiovascular and cerebral events compared to overweight patients without elevated NT-proBNP (HR 2.28).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: